OrbiMed’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

OrbiMed’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,822,463	Closed	-$319M	–	187
2020 Q4	$319M	Hold	13,822,463	–	–	2.79%	7
2020 Q3	$141M	Hold	13,822,463	–	–	1.77%	16
2020 Q2	$206M	Hold	13,822,463	–	–	2.9%	5
2020 Q1	$168M	Hold	13,822,463	–	–	2.83%	8
2019 Q4	$219M	Hold	13,822,463	–	–	3.12%	5
2019 Q3	$170M	Hold	13,822,463	–	–	3.22%	5
2019 Q2	$182M	Buy	+13,822,463	New	+$201M	2.83%	7

OrbiMed's PRVL Position: Q1 2021 in Review

OrbiMed sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 13,822,463 shares — an estimated $319M sold.

OrbiMed first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $319M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

OrbiMed reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 13,822,463 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $319M.
OrbiMed first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
OrbiMed's Prevail Therapeutics Inc. Common Stock position peaked at $319M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.